On Friday, Macrogenics Inc (NASDAQ: MGNX) opened lower -4.25% from the last session, before settling in for the closing price of $4.00. Price fluctuations for MGNX have ranged from $3.14 to $21.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 15.77% over the past five years. Company’s average yearly earnings per share was noted -1243.31% at the time writing. With a float of $58.46 million, this company’s outstanding shares have now reached $62.07 million.
Let’s look at the performance matrix of the company that is accounted for 339 employees.
Macrogenics Inc (MGNX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Macrogenics Inc is 6.66%, while institutional ownership is 104.56%. The most recent insider transaction that took place on Apr 04 ’24, was worth 799,148. In this transaction Senior VP and General Counsel of this company sold 51,395 shares at a rate of $15.55, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Senior VP and General Counsel sold 19,625 for $21.50, making the entire transaction worth $421,938. This insider now owns 8,895 shares in total.
Macrogenics Inc (MGNX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1243.31% per share during the next fiscal year.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Check out the current performance indicators for Macrogenics Inc (MGNX). In the past quarter, the stock posted a quick ratio of 3.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach -2.07 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Macrogenics Inc (NASDAQ: MGNX) saw its 5-day average volume 2.0 million, a positive change from its year-to-date volume of 1.85 million. As of the previous 9 days, the stock’s Stochastic %D was 13.33%. Additionally, its Average True Range was 0.46.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 4.21%, which indicates a significant decrease from 11.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 158.22% in the past 14 days, which was lower than the 258.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.58, while its 200-day Moving Average is $10.16. Nevertheless, the first resistance level for the watch stands at $3.95 in the near term. At $4.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.24. If the price goes on to break the first support level at $3.66, it is likely to go to the next support level at $3.50. Assuming the price breaks the second support level, the third support level stands at $3.38.
Macrogenics Inc (NASDAQ: MGNX) Key Stats
There are currently 62,633K shares outstanding in the company with a market cap of 239.87 million. Presently, the company’s annual sales total 58,750 K according to its annual income of -9,060 K. Last quarter, the company’s sales amounted to 9,100 K and its income totaled -52,190 K.
